Nurix signs $60M upfront, $3.4B milestone deal with Seagen for DAC cancer drugs

Nurix Therapeutics, Inc.

Nurix will use DELigase platform to develop protein degraders for conjugation to antibodies by Seagen.
Upfront cash payment of $60M; eligibility for up to $3.4B in research, development, regulatory and commercial milestones.
Tiered royalties: mid-single to low double digits on future sales; Nurix retains option for U.S. profit sharing and co-promotion on two products.
Seagen responsible for conjugation, preclinical/clinical development and commercialization of Degrader-Antibody Conjugates (DACs).

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

Nurix Therapeutics, Inc. entered into Collaboration Agreement with Seagen Inc. valued at $60 million (effective 2023-09-06).

Action: entry
Agreement: collaboration
Counterparty: Seagen Inc.
Value: $60 million
Effective: 2023-09-06

Exact text from the filing

On September 6, 2023, Nurix Therapeutics, Inc. (“Nurix” or the “Company”) entered into a Collaboration and License Agreement (the “Collaboration Agreement”) with Seagen Inc. (“Seagen”)

View on SEC.gov

Browse all material agreements →

Nurix Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001549595-23-000042

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.